DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR SEMAGLUTIDE
Clinical Trials for Semaglutide
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00696657 | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | Completed | Novo Nordisk A/S | Phase 2 | This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks. |
| NCT00813020 | A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects | Completed | Novo Nordisk A/S | Phase 1 | This trial is conducted in Europe. The aim of this clinical trial is to investigate whether differences exist between three different concentrations of the drug, NN9535, administered in healthy male subjects in equal doses. |
| NCT00833716 | Effect of Renal Impairment on the Pharmacokinetics of NN9535 | Completed | Novo Nordisk A/S | Phase 1 | This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535. |
| NCT00851773 | Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects | Completed | Novo Nordisk A/S | Phase 1 | This trial is conducted in Europe. The aim of this clinical trial is to assess and compare the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses of NN9535 in healthy male Japanese and Caucasian subjects. |
| NCT01272973 | Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects | Completed | Novo Nordisk A/S | Phase 1 | This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male subjects |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Semaglutide
Condition Name
Condition MeSH
Clinical Trial Locations for Semaglutide
Trials by Country
Clinical Trial Progress for Semaglutide
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Semaglutide
Sponsor Name
